ReviewNature reviews. Microbiology2006
Group B Streptococcus: global incidence and vaccine development.
Review in Nature reviews. Microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pathogenic characterization and drug resistance of neonatal sepsis in China: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Pooled it
- Vaginal chlorhexidine during labour to prevent early-onset neonatal group B streptococcal infection.The Cochrane database of systematic reviews · 2014Pooled it
- Streptococcus agalactiae carriage among pregnant women living in Rio de Janeiro, Brazil, over a period of eight years.PloS one · 2018Trial
- Role of pilus proteins in adherence and invasion of Streptococcus agalactiae to the lung and cervical epithelial cells.The Journal of biological chemistry · 2013Trial
- Increasing Antimicrobial Resistance Profile Diversity of Colonizing Group BAnnals of laboratory medicine · 2026Article
- Bacterial targeting of the neutrophil inhibitory receptor LILRB3 to evade antibody immunity.Nature communications · 2026Article
- Construction of a risk prediction model for premature rupture of membranes based on vaginal microecology and systemic inflammation: a prospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Cell SELEX-based DNA aptamer selection targetingVeterinary research forum : an international quarterly journal · 2026Article
- Structural and functional analysis reveals the catalytic mechanism and substrate binding mode of the broad-spectrum endolysin Ply2741.Virulence · 2025Article
- Article
- Article
- Review
- Isolation and characterization of Streptococcus agalactiae inducing mass mortalities in cultured Nile tilapia (Oreochromis niloticus) with trials for disease control using zinc oxide nanoparticles and ethanolic leaf extracts of some medicinal plants.BMC veterinary research · 2024Article
- Group B streptococcus colonization in pregnancy and neonatal outcomes: a three-year monocentric retrospective study during and after the COVID-19 pandemic.Italian journal of pediatrics · 2024Article
- Unmutated but T cell dependent IgM antibodies targeting Streptococcus suis play an essential role in bacterial clearance.PLoS pathogens · 2024Article
- Exploiting the Zebrafish Model for Sepsis Research: Insights into Pathophysiology and Therapeutic Potentials.Drug design, development and therapy · 2024Review
- A novel chimeric endolysin Cly2v shows potential in treating streptococci-induced bovine mastitis and systemic infections.Frontiers in microbiology · 2024Article
- Susceptibility Profile and Epidemiological Cut-Off Values Are Influenced by Serotype in Fish PathogenicAntibiotics (Basel, Switzerland) · 2023Article
- Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines.ACS infectious diseases · 2023Review
- Variable resistance to zinc intoxication amongFrontiers in immunology · 2023Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B Streptococcus (GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.